Moss J, Stevens L A, Cavanaugh E, Okazaki I J, Bortell R, Kanaitsuka T, Mordes J P, Greiner D L, Rossini A A
Pulmonary-Critical Care Medicine Branch, NHLBI, National Institutes of Health, Bethesda, Maryland 20892-1590, USA.
J Biol Chem. 1997 Feb 14;272(7):4342-6. doi: 10.1074/jbc.272.7.4342.
Rat RT6 proteins, and perhaps mouse Rt6, identify a set of immunoregulatory T lymphocytes. Rat RT6.1 (RT6.1) and rat RT6.2 (RT6. 2) are NAD glycohydrolases, which catalyze auto-ADP-ribosylation, but not ADP-ribosylation of exogenous proteins. Mouse Rt6.1 (mRt6.1) also catalyzes auto-ADP-ribosylation. The activity of mouse cytotoxic T lymphocytes is reportedly inhibited by ADP-ribosylation of surface proteins, raising the possibility that mRt6 may participate in this process. The reactions catalyzed by mRt6, would, however, need to be more diverse than those of the rat homologues and include the ADP-ribosylation of acceptors other than itself. To test this hypothesis, mRt6.1 and rat RT6.2 were synthesized in Sf9 insect cells and rat mammary adenocarcinoma (NMU) cells. mRt6.1, but not rat RT6.2, catalyzed the ADP-ribosylation of guanidino-containing compounds (e.g. agmatine). Unlike RT6.2, mRt6.1 was a weak NAD glycohydrolase. In the presence of agmatine, however, the ratio of [adenine-14C]ADP-ribosylagmatine formation from [adenine-14C]NAD to [carbonyl-14C]nicotinamide formation from [carbonyl-14C]NAD was approximately 1.0, demonstrating that mRt6.1 is primarily a transferase. ADP-ribosylarginine hydrolase, which preferentially hydrolyzes the alpha-anomer of ADP-ribosylarginine, released [U-14C]arginine from ADP-ribosyl[U-14C]arginine synthesized by mRT6.1, consistent with the conclusion that mRt6.1 catalyzes a stereospecific Sn2-like reaction. Thus, mRt6.1 is an NAD:arginine ADP-ribosyltransferase capable of catalyzing a multiple turnover, stereospecific Sn2-like reaction.
大鼠RT6蛋白,或许还有小鼠Rt6,可识别一组免疫调节性T淋巴细胞。大鼠RT6.1(RT6.1)和大鼠RT6.2(RT6.2)是NAD糖水解酶,可催化自身ADP-核糖基化,但不能催化外源蛋白的ADP-核糖基化。小鼠Rt6.1(mRt6.1)也能催化自身ADP-核糖基化。据报道,小鼠细胞毒性T淋巴细胞的活性会因表面蛋白的ADP-核糖基化而受到抑制,这增加了mRt6可能参与此过程的可能性。然而,mRt6催化的反应可能比大鼠同源物的反应更为多样,并且包括对自身以外的受体进行ADP-核糖基化。为了验证这一假设,在Sf9昆虫细胞和大鼠乳腺腺癌(NMU)细胞中合成了mRt6.1和大鼠RT6.2。mRt6.1能催化含胍基化合物(如鲱精胺)的ADP-核糖基化,而大鼠RT6.2则不能。与RT6.2不同,mRt6.1是一种较弱的NAD糖水解酶。然而,在有鲱精胺存在的情况下,由[腺嘌呤-14C]NAD形成[腺嘌呤-14C]ADP-核糖基鲱精胺与由[羰基-14C]NAD形成[羰基-14C]烟酰胺的比例约为1.0,这表明mRt6.1主要是一种转移酶。优先水解ADP-核糖基精氨酸α-异头物的ADP-核糖基精氨酸水解酶,从mRT6.1合成的ADP-核糖基[U-14C]精氨酸中释放出[U-14C]精氨酸,这与mRt6.1催化立体特异性类似Sn2反应的结论一致。因此,mRt6.1是一种NAD:精氨酸ADP-核糖基转移酶,能够催化多次周转的立体特异性类似Sn2反应。